{"filing":{"accession_number":"0001829126-26-008238","cik":"0002079109","ticker":null,"company_name":"Veraxa Biotech Holding AG","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"veraxabiotechag_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2079109/000182912626008238/veraxabiotechag_6k.htm"},"events":[{"id":22376,"run_id":20239,"accession_number":"0001829126-26-008238","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces VERAXA's patent portfolio strengthening, including first BiTAC-related patent applications filed in H1 2026 covering composition of matter, payload platforms, click chemistry, and conjugation technology. The company now holds over 50 granted patents across 26 families in 14 countries, with recently filed applications expected to protect core technology through 2047. This is a material operational/strategic milestone for a biotechnology company whose competitive advantage depends on intellectual property protection of its core BiTAC-TCE and BiTAC-ADC platforms.","company_name":"Veraxa Biotech Holding AG","ticker":null,"filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":[{"id":22299,"accession_number":"0001829126-26-008238","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces VERAXA's patent portfolio strengthening, including first BiTAC-related patent applications filed in H1 2026 covering composition of matter, payload platforms, click chemistry, and conjugation technology. The company now holds over 50 granted patents across 26 families in 14 countries, with recently filed applications expected to protect core technology through 2047. This is a material operational/strategic milestone for a biotechnology company whose competitive advantage depends on intellectual property protection of its core BiTAC-TCE and BiTAC-ADC platforms.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:10:07.306882+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22299,"accession_number":"0001829126-26-008238","item_number":"EX-99.1","item_title":"veraxabiotechag_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces VERAXA's patent portfolio strengthening, including first BiTAC-related patent applications filed in H1 2026 covering composition of matter, payload platforms, click chemistry, and conjugation technology. The company now holds over 50 granted patents across 26 families in 14 countries, with recently filed applications expected to protect core technology through 2047. This is a material operational/strategic milestone for a biotechnology company whose competitive advantage depends on intellectual property protection of its core BiTAC-TCE and BiTAC-ADC platforms.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:10:07.306882+00:00","company_name":"Veraxa Biotech Holding AG","ticker":null,"filing_date":"2026-07-31"}]}